# Legend Biotechnology

Carvykti 共同开发者 — BCMA、南京.

Source: https://cn.bioecon.ru/companies/legend-biotechnology/
Updated: 2026-07-11

- 国家: China
- 代码: LEGN

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | CARVYKTI在2025财年净贸易销售额为$1.9 billion；2026年第一季度净贸易销售额为$597 million | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://investors.legendbiotech.com/static-files/9d4e28b5-d67a-4af5-88c4-8649a1d17cfc, https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results, https://www.sec.gov/Archives/edgar/data/1801198/000117184325003764/exh_991.htm, https://www.sec.gov/Archives/edgar/data/1801198/000117184326000206/exh_991.htm |
| 员工人数 | 截至2026年3月员工约6,316人 | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results |
| 生产基地 | 美国新泽西州Raritan;比利时Ghent的Obelisc和Tech Lane(欧盟);新泽西州Morris Plains(CMO) | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://www.sec.gov/Archives/edgar/data/1801198/000117184325003764/exh_991.htm, https://www.sec.gov/Archives/edgar/data/1801198/000117184326000206/exh_991.htm |
| 产能 | 截至2026年,扩建后的Raritan工厂已安装产能可支持每年治疗多达10,000名患者 | https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results, https://www.sec.gov/Archives/edgar/data/1801198/000117184325003764/exh_991.htm, https://www.sec.gov/Archives/edgar/data/1801198/000117184326000206/exh_991.htm |
| 监管批准 | CARVYKTI已在美国、欧洲、日本、巴西、加拿大及中国获批用于复发/难治性多发性骨髓瘤(4线及以上) | https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-announces-acceptance-its-new-drug-application, https://investors.legendbiotech.com/static-files/7e441cf8-9f20-43de-ae9c-1bccf2b34e68, https://legendbiotech.gcs-web.com/node/8856/pdf, https://www.myeloma.org/treatment/carvykti-ciltacabtagene-autoleucel |
| 融资 | Janssen支付$3.5亿首付款以获得全球授权许可（2017年）；2020年纳斯达克上市毛收入$4.238亿 | https://www.sec.gov/Archives/edgar/data/1801198/000115752322000455/a52692636ex99_1.htm, https://www.thepharmaletter.com/ones-to-watch/legend-biotech |

独立来源: investors.legendbiotech.com, myeloma.org, sec.gov, thepharmaletter.com

## 技术

- [CAR-T 细胞疗法](https://cn.bioecon.ru/technology/car-t-cell-therapy/)